Octapharma USA, Inc. announced the U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection, for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children 6 years of age and older with von Willebrand disease (VWD).
Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, announced the closing of a $40M Series A financing round.
ImmunityBio, Inc.an immunotherapy company, announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.
CSafe, an active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, proudly announces the launch of a new line of cryogenic multi-use dewars for the cell and gene therapy market. The progressive technology, which is the first in CSafe's CGT Cryo Series, maintains temperatures colder than -150°C.
Fresenius, via its operating company Fresenius Kabi, announced the immediate U.S. availability of Tyenne® (tocilizumab-aazg), a biosimilar of Actemra® (tocilizumab). Tyenne®, for use in the treatment of chronic autoimmune diseases, is available in an intravenous (IV) formulation.
Can-Fite BioPharma a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announced that Biomedicines published an article titled “Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Hepatocellular Carcinoma (HCC)”. Biomedicines is a highly reputable journal that publishes articles on clinical and basic science topics in medicine.
ChromaTan, a bioprocessing and biotools advanced biomanufacturing technology platform development company, is excited to announce an alliance with Batavia Biosciences, a leading contract development and manufacturing organization, for the development and integration of ChromaTan’s BioRMBTM continuous counter-current elution technology into Batavia’s AAV HIP-Vax® manufacturing platform.
Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT).
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen® product portfolio is now third-party verified through the Alkemist Assured™ testing transparency program by Alkemist Labs.
STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.